A model predicting response to CGRP-inhibiting monoclonal antibodies is under development
How these new drugs fit into practice two years out from their first approvals
3-minute consult on general principles, recommendations, available options
New monoclonal antibody is first agent to address migraine prevention head-on
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Contraindication for migraine without aura based on decades old data
A Q&A with pediatric psychologist Ethan Benore, PhD